Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2015-08-27 Governance Information
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2015 Corporate Governance Statement 15 pages 601.2KB
Governance Information Classification · 100% confidence The document is titled 'CORPORATE GOVERNANCE STATEMENT' and extensively discusses the company's governance practices, board responsibilities, board composition, committees, and compliance with ASX Corporate Governance Principles. It references the Board Charter, Audit Committee, Nomination Committee, and Remuneration Committee charters, and details the governance framework rather than financial results or operational data. There is no indication of financial statements, audit opinions, or regulatory certifications. The content aligns with a Governance Information report, which details internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed content confirm it is the report itself, not a brief announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2015-08-27 English
Appendix 3B 9 pages 470.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new shares, options, exercise prices, escrowed shares, and related securities information. The document references ASX (Australian Securities Exchange) rules and compliance, and it is clearly an announcement related to capital raising and securities issuance. There is no financial performance data, earnings information, or management discussion. The content aligns with updates on company fundraising and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance data, confirming it is not a mere announcement of a report but the actual filing of the capital issuance details.
2015-08-25 English
Mayne Pharma launches Doryx 50mg Tablet 2 pages 244.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 August 2015 from Mayne Pharma Group Limited about the launch of a new pharmaceutical product, Doryx 50 mg tablets. It contains promotional and product information, safety details, and contact information. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate announcement about a product launch rather than a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement, which corresponds to Regulatory Filings (RNS). The document length is 5747 characters, which is sufficient for a full announcement but does not contain financial data or detailed report content.
2015-08-09 English
Ceasing to be a substantial holder 4 pages 41.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder filed under section 671B of the Corporations Act 2001. It details changes in shareholding interests and the cessation of substantial holding status by Thorney International Pty Ltd in Mayne Pharma Group Limited. The document is a regulatory notification about changes in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a formal notice of shareholding changes.
2015-08-06 English
Mayne Pharma appoints new senior management 2 pages 247.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 5 August 2015, detailing the appointment of two new executives to Mayne Pharma's leadership team: a global leader of corporate and business development and a new CFO for Mayne Pharma USA. The content focuses on management changes and executive appointments, with no financial data, report references, or regulatory filings mentioned. The document length is 3844 characters, which is relatively short and consistent with a management announcement rather than a full report or earnings release. Therefore, the document fits best under the category of Board/Management Information (MANG).
2015-08-04 English
Appendix 3B 9 pages 469.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically the issuance of ordinary shares and employee options under an employee share option plan. It includes detailed information about the class, number, terms, issue price, purpose of the securities, and compliance with ASX listing rules. The document is a formal notification to the Australian Securities Exchange (ASX) about a capital raising event involving new share issuance and application for quotation of additional securities. It does not contain financial statements, earnings data, management discussion, or audit information. Instead, it focuses on the capital structure change and securities issuance details. Therefore, this document fits the category of a Capital/Financing Update (CAP). The document length is over 13,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement. Hence, the classification is CAP with high confidence.
2015-08-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.